Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 42 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung CancerCompletedNCT04263051Phase 2
• Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung CancerWithdrawnNCT04262869Phase 2
• Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerCompletedNCT04262856Phase 2
• A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA MethylationWithdrawnNCT04262388Phase 2
• A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic CancersTerminatedNCT04260802Phase 1/2
• Onco-primary Care Networking to Support TEAM-based CareActive, not recruitingNCT04258813Not applicable
• Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized StudyActive, not recruitingNCT04258137Not applicable
• A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)CompletedNCT04258033Phase 2
• Bevacizumab Versus Docetaxel/Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non Small Cell Lung CancerCompletedNCT04257864
• Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04255836Phase 2
• A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
• Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung CancerStatus unknownNCT04252365Phase 2
• Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04245514Phase 2
• A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerStatus unknownNCT04239833Phase 3
• Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLCCompletedNCT04238169Phase 2
• Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following ResectionCompletedNCT04238130
• Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationCompletedNCT04233021Phase 2
• Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung CancersCompletedNCT04230408Phase 2
• Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLCActive, not recruitingNCT04227028Phase 1
• Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid CarcinomaCompletedNCT04224337Phase 2
• Clinical Utility of Liquid Biopsy in Brigatinib ALK+ PatientsActive, not recruitingNCT04223596Phase 2
• Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer PatientsCompletedNCT04222335Not applicable
• Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Phase 1
• Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT04213170Phase 2
• Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung CancerCompletedNCT04212052Phase 2
• Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibTerminatedNCT04211922Phase 2
• Anlotinib Combined With Nivolumab for Non-Small Cell Lung CancerStatus unknownNCT04211896Phase 2
• Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLCStatus unknownNCT04211090Phase 2
• Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC)Status unknownNCT04208854
• Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI TherapyCompletedNCT04207775
• D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCCompletedNCT04206072Phase 2/3
• Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer PatientsCompletedNCT04205552Phase 2
• A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive MutationCompletedNCT04204473Phase 1
• INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)WithdrawnNCT04203511Phase 3
• Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04203485Phase 3
• Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung CancerStatus unknownNCT04199559Phase 1/2
• WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System MetastasesActive, not recruitingNCT04197934Phase 1
• Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIBStatus unknownNCT04197076
• A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)CompletedNCT04194203Phase 3
• Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLCStatus unknownNCT04193098Phase 1
• The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLCStatus unknownNCT04193007Phase 2
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid TumorsTerminatedNCT04190628Phase 1
• Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung CarcinomaCompletedNCT04189679
• An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung CancerTerminatedNCT04189614Phase 1
• LITT and Pembrolizumab in Recurrent Brain MetastasisTerminatedNCT04187872Phase 1
• Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung CancerCompletedNCT04187768
• [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed TherapyWithdrawnNCT04186988Early Phase 1
• Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC PatientsCompletedNCT04184921Phase 2
• Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLCStatus unknownNCT04182698Phase 1/2
• A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung CancerStatus unknownNCT04181372Phase 2
• Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionActive, not recruitingNCT04180371Phase 1/2
• A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC PatientsCompletedNCT04177290Phase 1
• A Nutritional Supplement to Support People With Non-small Cell Lung CancerActive, not recruitingNCT04175769Not applicable
• Clinical Trial in Chinese Healthy Volunteers of GB222Status unknownNCT04175158Phase 1
• Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant MesotheliomaTerminatedNCT04173338Phase 1
• SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung CancerTerminatedNCT04171284Phase 3
• The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLCTerminatedNCT04170959Phase 2
• A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLCStatus unknownNCT04167774Phase 2
• SinTilimab After Radiation (STAR Study)CompletedNCT04167657Phase 2
• Plasma-Adapted First-Line Pembro In NSCLCActive, not recruitingNCT04166487Phase 2
• KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)CompletedNCT04165083Phase 2
• Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung CancerStatus unknownNCT04164745Phase 2
• Fully Automated Pipeline for the Detection and Segmentation of Non-Small Cell Lung Cancer (NSCLC) on CT ImagesStatus unknownNCT04164186
• Green Tea Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung CancerWithdrawnNCT04160559Not applicable
• Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLCCompletedNCT04158440Phase 3
• Appropriate Dosing to Optimise Personalised Cancer TreatmentsCompletedNCT04154163
• Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung CancerStatus unknownNCT04153799Phase 1
• Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLCStatus unknownNCT04153734Phase 2
• Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLCStatus unknownNCT04153097
• Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Phase 1/2
• A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWithdrawnNCT04151563Phase 1/2
• Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04148898Phase 2
• ctDNA Guided Treatment of Early Resistance to Targeted TreatmentCompletedNCT04148066Not applicable
• AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.Status unknownNCT04145232
• Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLCCompletedNCT04144608Phase 2
• Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung CancerCompletedNCT04144582Phase 2
• Study of DF1001 in Patients With Advanced Solid TumorsCompletedNCT04143711Phase 1/2
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingNCT04140526Phase 1/2
• Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsActive, not recruitingNCT04140500Phase 1/2
• Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene MutationStatus unknownNCT04137718
• Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung CancerStatus unknownNCT04137588
• BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and DiagnosticsStatus unknownNCT04136470
• Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLCStatus unknownNCT04133337Phase 1/2
• Phase II Study With Cabozantinib in Patients With RET Positive NSCLCStatus unknownNCT04131543Phase 2
• Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabActive, not recruitingNCT04130516Phase 1/2
• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsCompletedNCT04129502Phase 3
• Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC PatientsActive, not recruitingNCT04127110Phase 2
• Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)Status unknownNCT04124731Phase 2
• Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04123379Phase 2
• Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLCStatus unknownNCT04116918
• Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsTerminatedNCT04116320Phase 1
• PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort StudyStatus unknownNCT04115410
• A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung CancerStatus unknownNCT04111913Phase 2
• Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung CancerCompletedNCT04111705Phase 2
• Immunotherapy in Patient With Poor General ConditionCompletedNCT04108026Phase 2
• SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLCStatus unknownNCT04106180Phase 2
• Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorApproved for marketingNCT04100694
• Outcomes of Surgical Resection After Induction Treatment in Non-Small Cell Lung Cancer (SRaIT)CompletedNCT04092465
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerActive, not recruitingNCT04092283Phase 3
• Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLCCompletedNCT04087473

← Carcinoma, Non-Small-Cell Lung overview